Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

668 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Surveillance cultures of blood, urine, and throat specimens are not valuable for predicting cytomegalovirus disease in liver transplant recipients. Boston Center for Liver Transplantation Cytomegalovirus Immune Globulin Study Group.
Falagas ME, Snydman DR, Ruthazer R, Werner BG, Griffith J. Falagas ME, et al. Clin Infect Dis. 1997 May;24(5):824-9. doi: 10.1093/clinids/24.5.824. Clin Infect Dis. 1997. PMID: 9142776
Incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME, Snydman DR, George MJ, Werner B, Ruthazer R, Griffith J, Rohrer RH, Freeman R. Falagas ME, et al. Transplantation. 1996 Jun 27;61(12):1716-20. doi: 10.1097/00007890-199606270-00009. Transplantation. 1996. PMID: 8685949 Clinical Trial.
Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study.
Snydman DR, Falagas ME, Avery R, Perlino C, Ruthazer R, Freeman R, Rohrer R, Fairchild R, O'Rourke E, Hibberd P, Werner BG. Snydman DR, et al. Among authors: falagas me. Transplant Proc. 2001 Jun;33(4):2571-5. doi: 10.1016/s0041-1345(01)02101-7. Transplant Proc. 2001. PMID: 11406251 Clinical Trial. No abstract available.
Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection.
DesJardin JA, Gibbons L, Cho E, Supran SE, Falagas ME, Werner BG, Snydman DR. DesJardin JA, et al. Among authors: falagas me. J Infect Dis. 1998 Dec;178(6):1783-6. doi: 10.1086/314510. J Infect Dis. 1998. PMID: 9815234 Clinical Trial.
Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis.
Falagas ME, Paya C, Ruthazer R, Badley A, Patel R, Wiesner R, Griffith J, Freeman R, Rohrer R, Werner BG, Snydman DR. Falagas ME, et al. Transplantation. 1998 Oct 27;66(8):1020-8. doi: 10.1097/00007890-199810270-00010. Transplantation. 1998. PMID: 9808486
Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME, Snydman DR, Ruthazer R, Griffith J, Werner BG, Freeman R, Rohrer R. Falagas ME, et al. Clin Transplant. 1997 Oct;11(5 Pt 1):432-7. Clin Transplant. 1997. PMID: 9361936 Clinical Trial.
Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME, Snydman DR, Griffith J, Werner BG, Freeman R, Rohrer R. Falagas ME, et al. Clin Infect Dis. 1997 Aug;25(2):314-7. doi: 10.1086/514555. Clin Infect Dis. 1997. PMID: 9332531
The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.
George MJ, Snydman DR, Werner BG, Griffith J, Falagas ME, Dougherty NN, Rubin RH. George MJ, et al. Among authors: falagas me. Am J Med. 1997 Aug;103(2):106-13. doi: 10.1016/s0002-9343(97)80021-6. Am J Med. 1997. PMID: 9274893
Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients.
Falagas ME, Arbo M, Ruthazer R, Griffith JL, Werner BG, Rohrer R, Freeman R, Lewis WD, Snydman DR. Falagas ME, et al. Transplantation. 1997 Jun 15;63(11):1595-601. doi: 10.1097/00007890-199706150-00010. Transplantation. 1997. PMID: 9197352 Clinical Trial.
Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME, Snydman DR, Griffith J, Ruthazer R, Werner BG. Falagas ME, et al. Ann Intern Med. 1997 Feb 15;126(4):275-9. doi: 10.7326/0003-4819-126-4-199702150-00003. Ann Intern Med. 1997. PMID: 9036799 Clinical Trial.
668 results
Jump to page
Feedback